Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use KEBILIDI safely and effectively. See full prescribing information for KEBILIDI. KEBILIDI (eladocagene exuparvovec-tneq) suspension, for intraputaminal infusion Initial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under accelerated approval based on the change from baseline in gross motor milestone achievement at 48 weeks post treatment [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
- generic_name
- eladocagene exuparvovec-tneq
- product_names
- eladocagene exuparvovec-tneq
- ndc
- 52856-601, 52856-601-11, 52856-601-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en